Reducing Tx may harm safety in early HPV+ oropharyngeal cancer
(HealthDay)—For patients with human papillomavirus (HPV)+ stage I or II oropharyngeal cancer, deintensification of treatment from chemoradiotherapy to one modality may compromise safety, according to a study published online ...